NO803910L - Fremgangsmaate for immunologisk paavisning av kreft i vev hos mennesker. - Google Patents
Fremgangsmaate for immunologisk paavisning av kreft i vev hos mennesker.Info
- Publication number
- NO803910L NO803910L NO803910A NO803910A NO803910L NO 803910 L NO803910 L NO 803910L NO 803910 A NO803910 A NO 803910A NO 803910 A NO803910 A NO 803910A NO 803910 L NO803910 L NO 803910L
- Authority
- NO
- Norway
- Prior art keywords
- antibodies
- cells
- nucleoli
- human
- antigens
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 56
- 238000000034 method Methods 0.000 title claims description 46
- 201000011510 cancer Diseases 0.000 title claims description 31
- 238000001514 detection method Methods 0.000 title claims description 11
- 230000001900 immune effect Effects 0.000 title claims description 6
- 210000004027 cell Anatomy 0.000 claims description 67
- 239000000427 antigen Substances 0.000 claims description 61
- 102000036639 antigens Human genes 0.000 claims description 61
- 108091007433 antigens Proteins 0.000 claims description 61
- 108010089610 Nuclear Proteins Proteins 0.000 claims description 52
- 102000007999 Nuclear Proteins Human genes 0.000 claims description 52
- 210000001519 tissue Anatomy 0.000 claims description 28
- 239000000284 extract Substances 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 19
- 230000003211 malignant effect Effects 0.000 claims description 17
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 16
- 238000001493 electron microscopy Methods 0.000 claims description 10
- 210000005260 human cell Anatomy 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 238000000386 microscopy Methods 0.000 claims description 9
- 238000000376 autoradiography Methods 0.000 claims description 8
- 238000000799 fluorescence microscopy Methods 0.000 claims description 8
- 230000003053 immunization Effects 0.000 claims description 8
- 230000000984 immunochemical effect Effects 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 238000002372 labelling Methods 0.000 claims description 6
- 230000004807 localization Effects 0.000 claims description 6
- 239000007850 fluorescent dye Substances 0.000 claims description 5
- 238000001155 isoelectric focusing Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 102000019040 Nuclear Antigens Human genes 0.000 claims description 4
- 108010051791 Nuclear Antigens Proteins 0.000 claims description 4
- 102000003992 Peroxidases Human genes 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000002649 immunization Methods 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 4
- 201000001514 prostate carcinoma Diseases 0.000 claims description 4
- 239000000375 suspending agent Substances 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 3
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 3
- 230000002489 hematologic effect Effects 0.000 claims description 3
- 238000012800 visualization Methods 0.000 claims description 3
- -1 8-galactosidase Proteins 0.000 claims description 2
- 102000014914 Carrier Proteins Human genes 0.000 claims description 2
- 102000008857 Ferritin Human genes 0.000 claims description 2
- 108050000784 Ferritin Proteins 0.000 claims description 2
- 238000008416 Ferritin Methods 0.000 claims description 2
- 108091008324 binding proteins Proteins 0.000 claims description 2
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 claims description 2
- 230000002380 cytological effect Effects 0.000 claims 2
- 238000003306 harvesting Methods 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 claims 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 102000018832 Cytochromes Human genes 0.000 claims 1
- 108010052832 Cytochromes Proteins 0.000 claims 1
- 229920005654 Sephadex Polymers 0.000 claims 1
- 239000012507 Sephadex™ Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000001166 ammonium sulphate Substances 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 238000005341 cation exchange Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000004440 column chromatography Methods 0.000 claims 1
- 230000007717 exclusion Effects 0.000 claims 1
- 238000005227 gel permeation chromatography Methods 0.000 claims 1
- 108060003552 hemocyanin Proteins 0.000 claims 1
- 239000004816 latex Substances 0.000 claims 1
- 229920000126 latex Polymers 0.000 claims 1
- 238000000691 measurement method Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000010397 one-hybrid screening Methods 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 24
- 239000002953 phosphate buffered saline Substances 0.000 description 24
- 210000004940 nucleus Anatomy 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 15
- 238000010166 immunofluorescence Methods 0.000 description 14
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 12
- 238000011835 investigation Methods 0.000 description 11
- 239000008188 pellet Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000007983 Tris buffer Substances 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 102000004389 Ribonucleoproteins Human genes 0.000 description 6
- 108010081734 Ribonucleoproteins Proteins 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000000265 homogenisation Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 208000010454 Experimental Liver Neoplasms Diseases 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000004238 cell nucleolus Anatomy 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 230000003169 placental effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000001855 preneoplastic effect Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000031864 metaphase Effects 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- GYQWVHROHDZXRS-UHFFFAOYSA-N [1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azanium;carbonate Chemical compound OC(O)=O.OCC(N)(CO)CO.OCC(N)(CO)CO GYQWVHROHDZXRS-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 239000007982 barbital buffer Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010218 electron microscopic analysis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000031877 prophase Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 206010043688 thyroid adenoma Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Detergent Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO864091A NO864091D0 (no) | 1980-01-04 | 1986-10-14 | Antigener fra isolerte nukleoli og nukleaere ekstrakter samt diagnostisk utstyr for bruk ved immunologisk paavisning av krefter. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000343088A CA1157373A (en) | 1980-01-04 | 1980-01-04 | Detection of human cancer cells with antibodies to human cancer nucleolar antigen(s) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO803910L true NO803910L (no) | 1981-07-06 |
Family
ID=4115973
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO803910A NO803910L (no) | 1980-01-04 | 1980-12-22 | Fremgangsmaate for immunologisk paavisning av kreft i vev hos mennesker. |
| NO850005A NO850005L (no) | 1980-01-04 | 1985-01-02 | Nukleaert preparat, fremgangsmaate for rensing av nukleolaere antigener samt fremgangsmaate for rensing av antistoffer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO850005A NO850005L (no) | 1980-01-04 | 1985-01-02 | Nukleaert preparat, fremgangsmaate for rensing av nukleolaere antigener samt fremgangsmaate for rensing av antistoffer |
Country Status (27)
| Country | Link |
|---|---|
| JP (1) | JPS56101553A (de) |
| KR (1) | KR850001770B1 (de) |
| AR (1) | AR232046A1 (de) |
| AT (1) | AT373397B (de) |
| AU (1) | AU535024B2 (de) |
| BE (1) | BE886935A (de) |
| CA (1) | CA1157373A (de) |
| CH (1) | CH659328A5 (de) |
| DE (1) | DE3047654A1 (de) |
| DK (1) | DK554980A (de) |
| ES (2) | ES498305A0 (de) |
| FI (1) | FI810007L (de) |
| FR (1) | FR2484650B1 (de) |
| GB (1) | GB2067286B (de) |
| GR (1) | GR72850B (de) |
| IE (1) | IE50760B1 (de) |
| IL (1) | IL61641A (de) |
| IT (1) | IT1172216B (de) |
| LU (1) | LU83015A1 (de) |
| NL (1) | NL8007128A (de) |
| NO (2) | NO803910L (de) |
| NZ (1) | NZ195756A (de) |
| OA (1) | OA06713A (de) |
| PH (5) | PH18765A (de) |
| PT (1) | PT72301B (de) |
| SE (1) | SE450665B (de) |
| ZA (1) | ZA807754B (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4487830A (en) * | 1982-05-14 | 1984-12-11 | American Hoechst Corporation | Enzyme/immunofluorescent assay for autoantibodies |
| JPS5990052A (ja) * | 1982-11-16 | 1984-05-24 | Katsu Taniguchi | モノクロ−ナル特異抗体を用いたメラノ−マ診断薬 |
| US4871661A (en) * | 1983-11-23 | 1989-10-03 | The Ohio State University Research Foundation | Process for testing the carcinogenicity of a material or the presence of cancer-inducing factors in an environment |
| US4746539A (en) * | 1983-11-23 | 1988-05-24 | The Ohio State University Research Foundation | Purification of cancer-associated protein and preparation of antibody thereto |
| EP0145373B1 (de) * | 1983-11-23 | 1992-03-25 | The Ohio State University Research Foundation | Reinigung eines krebsassoziierten Proteins und Herstellung eines Antikörpers dazu |
| US4645737A (en) * | 1984-03-05 | 1987-02-24 | American Hoechst Corporation | Enzyme/immunofluorescent assay for anti-treponemal antibodies |
| US4607008A (en) * | 1984-03-05 | 1986-08-19 | American Hoechst Corporation | Enzyme/immunofluorescent assay for anti-Epstein-Barr Virus antibodies |
| ATE76509T1 (de) * | 1984-05-02 | 1992-06-15 | Univ Research Corp | Immunologisches testverfahren eines prokoagulierenden enzyms zum nachweis von krebs. |
| US4616658A (en) * | 1985-02-27 | 1986-10-14 | William Shell | Non-radioactively labeled microspheres and use of same to measure blood flow |
| US4798719A (en) * | 1986-09-11 | 1989-01-17 | University Of Pittsburgh | Method for selection of antigens suitable as in vivo targets for antibodies |
| US5019368A (en) * | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| US4861581A (en) * | 1986-12-05 | 1989-08-29 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| CA2023030A1 (en) * | 1990-07-13 | 1992-01-14 | Robert R. Guerrero | In vitro method and probe for detecting the presence of the ring shaped particle and malignancy in humans and animals |
-
1980
- 1980-01-04 CA CA000343088A patent/CA1157373A/en not_active Expired
- 1980-12-04 AU AU65070/80A patent/AU535024B2/en not_active Ceased
- 1980-12-04 IE IE2533/80A patent/IE50760B1/en unknown
- 1980-12-04 NZ NZ195756A patent/NZ195756A/xx unknown
- 1980-12-05 IL IL61641A patent/IL61641A/xx unknown
- 1980-12-10 ZA ZA00807754A patent/ZA807754B/xx unknown
- 1980-12-15 PH PH24978A patent/PH18765A/en unknown
- 1980-12-17 DE DE19803047654 patent/DE3047654A1/de active Granted
- 1980-12-18 LU LU83015A patent/LU83015A1/fr unknown
- 1980-12-22 NO NO803910A patent/NO803910L/no unknown
- 1980-12-22 AR AR283753A patent/AR232046A1/es active
- 1980-12-27 JP JP18948880A patent/JPS56101553A/ja active Pending
- 1980-12-29 DK DK554980A patent/DK554980A/da not_active Application Discontinuation
- 1980-12-30 KR KR1019800005026A patent/KR850001770B1/ko active
- 1980-12-30 CH CH9652/80A patent/CH659328A5/de not_active IP Right Cessation
- 1980-12-31 PT PT72301A patent/PT72301B/pt unknown
- 1980-12-31 NL NL8007128A patent/NL8007128A/nl not_active Application Discontinuation
- 1980-12-31 BE BE0/203378A patent/BE886935A/fr not_active IP Right Cessation
- 1980-12-31 GB GB8041638A patent/GB2067286B/en not_active Expired
-
1981
- 1981-01-02 FR FR8100014A patent/FR2484650B1/fr not_active Expired
- 1981-01-02 FI FI810007A patent/FI810007L/fi not_active Application Discontinuation
- 1981-01-02 ES ES498305A patent/ES498305A0/es active Granted
- 1981-01-02 SE SE8100011A patent/SE450665B/sv not_active IP Right Cessation
- 1981-01-05 AT AT0001081A patent/AT373397B/de not_active IP Right Cessation
- 1981-01-05 GR GR63789A patent/GR72850B/el unknown
- 1981-01-05 IT IT67001/81A patent/IT1172216B/it active
- 1981-01-05 OA OA57289A patent/OA06713A/xx unknown
-
1982
- 1982-02-01 ES ES509239A patent/ES8307377A1/es not_active Expired
-
1983
- 1983-02-21 PH PH28548A patent/PH18624A/en unknown
- 1983-02-21 PH PH28550A patent/PH18129A/en unknown
- 1983-02-21 PH PH28549A patent/PH18636A/en unknown
- 1983-02-21 PH PH28547A patent/PH18637A/en unknown
-
1985
- 1985-01-02 NO NO850005A patent/NO850005L/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kerjaschki et al. | Identification of a major sialoprotein in the glycocalyx of human visceral glomerular epithelial cells. | |
| Gauthier et al. | Distribution and properties of myosin isozymes in developing avian and mammalian skeletal muscle fibers | |
| Coons et al. | Localization of antigen in tissue cells: II. Improvements in a method for the detection of antigen by means of fluorescent antibody | |
| NO803910L (no) | Fremgangsmaate for immunologisk paavisning av kreft i vev hos mennesker. | |
| Bhattacharya et al. | Immunologic studies of human serous cystadenocarcinoma of ovary. Demonstration of tumor‐associated antigens | |
| KR100191118B1 (ko) | 불임화 및 피임용 조나펠루시다항원과 항체의 제법과 용도 | |
| Gosseye et al. | An immunohistological comparison of the secretory capacity of villous and extravillous trophoblast in the human placenta | |
| Phillips et al. | Tumour angiogenesis factor (TAF) and its neutralisation by a xenogeneic antiserum | |
| Fargnoli et al. | Identification of vitelline membrane proteins in Drosophila melanogaster | |
| Colombatti et al. | Glycoprotein 115, a glycoprotein isolated from chick blood vessels, is widely distributed in connective tissue. | |
| Anderson et al. | Immunofluorescence studies on the localization of relaxin in the corpus luteum of the pregnant rat | |
| Ten Have-Opbroek | Immunological study of lung development in the mouse embryo: II. First appearance of the great alveolar cell, as shown by immunofluorescence microscopy | |
| US4448890A (en) | Detection of human cancer cells with antibodies to human cancer nucleolar antigens | |
| JP2784200B2 (ja) | 細胞組織標本の起源の同定方法 | |
| Koehler et al. | Fine structure observations on the distribution of antigenic sites on guinea pig spermatozoa | |
| NO864091L (no) | Antigener fra isolerte nukleoli og nukleaere ekstrakter samt diagnostisk utstyr for bruk ved immunologisk paavisning av kreft. | |
| EP0689552B1 (de) | Methode zur detektion von rissen in amniomembranen bei schwangeren säugetieren | |
| US4794077A (en) | Detection of human cancer cells with anitbodies to human cancer nucleolar antigen p145 | |
| EP0007214A1 (de) | Mittel zum Nachweis der Anwesenheit krebsartiger oder bösartiger Tumorzellen | |
| Hanqing et al. | Isolation, characterization, and localization of the zona pellucida binding proteins of boar sperm | |
| Sulitzeanu | Antigenic components of rat connective tissue. | |
| Misra | Glomerular basement membrane antigens of Masugi nephritis | |
| US5047508A (en) | Monoclonal antibody to MHS-5; a new probe for sexual assault analysis | |
| NZ215887A (en) | Tissue extracts with antitumor properties and compositions of them | |
| US4840915A (en) | Method for diagnosing malignant tumors |